Anti-CD137 antibodies and method of treating colorectal cancer using them

US12252542B2 · kind B2 · utility

Assignee

• Shihuida Pharmaceutical Group (Jilin) Co., Ltd. · CN

Inventors

• Xin Zhang · Philadelphia, US
• Jianjian PENG · 安丰镇, CN
• Kai Fu · Palo Alto, US
• Hui Ma · Tuji, CN
• Xiaolong PAN · 安丰镇, CN
• Shilong FU · 安丰镇, CN
• Shuli Ma · 安丰镇, CN
• Jian-Hua Ding · San Diego, US

Key dates

• Filing date: Sep 12, 2019
• Grant date: Mar 18, 2025
• Expiry date: Jun 16, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An antibody may be capable of specifically binding CD137 or an antigen binding fragment thereof, wherein the light chain variable region and the heavy chain variable region have one or more mutations. The antibody or antigen binding fragment thereof may be used in preparing a drug. The antibody or an antigen binding fragment thereof may specifically bind CD137, and may include a light chain variable region VL and a heavy chain variable region VH, wherein compared to a sequence as shown in SEQ ID NO: 103, the VL comprises one or more VL amino acid mutations, and the VL amino acid mutation occurs at one or more positions: V3, A10, K44, D71, and/or V77.